Business
CohBar Announces the Appointment of Dr. Philippe Calais to its Board
CohBar Announces the Appointment of Dr. Philippe Calais to its Board.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\nMENLO PARK, Calif., June 07, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) (“CohBar” or the “Company”), an innovative biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the appointment of Philippe P. Calais, Ph.D., to its Board of Directors, and to the Board’s Audit Committee.  \n “Philippe’s extensive management experience, from early stage biotech to large pharmaceutical companies, adds significant complementary experience to the CohBar board,” said Albion Fitzgerald, CohBar Chairman. “Our strengthened Board is well positioned to provide strategic guidance as we approach the clinic with our lead program, and prioritize our early stage pipeline for further development. We’re very pleased to have Philippe join the company at such an exciting time for CohBar.” About Dr. Calais Dr. Calais has over 30 years of biotech and pharmaceutical industry experience both in North America and Europe, and for the past 6 years has served as the president and chief executive officer of Isarna Therapeutics B.V. (“Isarna”), a developer of oligonucleotide therapeutics. Dr. Calais also served, from 2017-2018, as a director and audit committee member of Marina Biotech Inc. (OTCQB:MRNA), and has been an economic advisor to the French government since 2013. Prior to becoming CEO of Isarna, Dr. Calais managed several biopharmaceutical companies in Canada and in Europe and headed a large technology transfer organization for the University of Montreal. Earlier in his career Dr. Calais held senior management positions at F. Hoffmann-La Roche and Servier Canada. Dr. Calais received his bachelor’s degree in pharmacy and his doctor of pharmacy from the Université François-Rabelais in Tours, France, in 1985 and 1987, respectively. About CohBar’s Lead Program CohBar’s lead program is based on CB4211, a first-in-class mitochondria based therapeutic (MBT) that has demonstrated significant therapeutic potential in preclinical models of nonalcoholic steatohepatitis (NASH) and obesity. CB4211 is a novel and improved analog of MOTS-c, a naturally occurring mitochondrial-derived peptide (MDP) which was discovered in 2012 by CohBar founder Dr. Pinchas Cohen and his academic c...